post-infectious cough
Conditions
Interventions
Control Group :Placebo (Shufeng Huashi Granules Simulant)
Treatment Group :Shufeng Huashi Granules
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1)Aged between 18 and 65 years (inclusive) at the time of signing the informed consent form; (2)Diagnosed with post-infectious cough according to Western medicine diagnostic criteria; (3)Identified as having the Traditional Chinese Medicine (TCM) syndrome of wind exuberance and dampness obstruction; (4)Cough symptom score = 3 points; (5)Voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Cough caused by other etiologies, such as cough variant asthma (CVA), upper airway cough syndrome (UACS), eosinophilic bronchitis (EB), gastroesophageal reflux-related cough (GERC), allergic cough (AC), chronic bronchitis, etc., as well as persistent cough symptoms prior to this infection; (2) Participants with severe pulmonary diseases (e.g., chronic obstructive pulmonary disease, lung cancer, tuberculosis); (3) Participants who have taken angiotensin-converting enzyme inhibitors (ACEI) within the past month; (4) Current smokers or those who have quit smoking for less than 3 months; (5) Participants with severe cardiovascular, cerebrovascular, malignant tumor, hematological, gastrointestinal, or other systemic diseases, or severe or progressive diseases; or those with severe mental disorders, severe cognitive impairment, etc., who are unable or unwilling to cooperate; (6) Participants with impaired liver or kidney function: ALT or AST > 2 times the upper limit of normal reference values; and/or serum creatinine > 1.5 times the upper limit of normal reference values; (7) Participants with white blood cell count 10.0×109/L; and/or neutrophil (N) classification > 80%; (8) Participants with body temperature (axillary) = 37.3?; (9) Participants with allergic constitution (allergic to 2 or more substances) or allergy to the investigational drug or its components; (10) Participants with a history of long-term alcohol abuse or drug addiction; (11) Pregnant, breastfeeding women, or women planning pregnancy; (12) Participants who have received or are currently receiving other drug clinical trials within the past 3 months; (13) Participants deemed unsuitable for participation by the investigator (e.g., poor compliance).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough Relief Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cough Symptom Score;Simplified Cough Severity Score;TCM Syndrome Efficacy;Leicester Cough Questionnaire (LCQ) Score;Cough Relief Rate;Cough cure rate;Time to Cough Resolution;Time to Cough Alleviation;Cough Recurrence Rate; | — |
Countries
China
Contacts
Public ContactZhang Hongchun
China-Japan Friendship Hospital
Outcome results
None listed